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Dynamic and Modularized
MicroRNA Regulation and Its
Implication in Human Cancers
Jiang Shu1, Bruno Vieira Resende e Silva1, Tian Gao1, Zheng Xu2,3 & Juan Cui1
MicroRNA is responsible for the fine-tuning of fundamental cellular activities and human disease
development. The altered availability of microRNAs, target mRNAs, and other types of endogenous
RNAs competing for microRNA interactions reflects the dynamic and conditional property of microRNAmediated gene regulation that remains under-investigated. Here we propose a new integrative method
to study this dynamic process by considering both competing and cooperative mechanisms and
identifying functional modules where different microRNAs co-regulate the same functional process.
Specifically, a new pipeline was built based on a meta-Lasso regression model and the proof-of-concept
study was performed using a large-scale genomic dataset from ~4,200 patients with 9 cancer types.
In the analysis, 10,726 microRNA-mRNA interactions were identified to be associated with a specific
stage and/or type of cancer, which demonstrated the dynamic and conditional miRNA regulation during
cancer progression. On the other hands, we detected 4,134 regulatory modules that exhibit high fidelity
of microRNA function through selective microRNA-mRNA binding and modulation. For example,
miR-18a-3p, −320a, −193b-3p, and −92b-3p co-regulate the glycolysis/gluconeogenesis and focal
adhesion in cancers of kidney, liver, lung, and uterus. Furthermore, several new insights into dynamic
microRNA regulation in cancers have been discovered in this study.
Mature microRNAs (miRNAs) are typically 20–25 nucleotides long. They hybridize with complementary
sequences in the 3′-untranslated regions (UTRs) in messenger RNAs (mRNAs) and silence protein-coding genes
through destabilizing mRNA or preventing translation of mRNA1. In humans, it was estimated that 2,588 miRNAs regulate over 60% of human genes and participate in every aspect of cellular activities in cell growth and
cell death2. During the past decade, numerous studies have disclosed the regulatory roles of miRNAs in both the
fundamental cellular processes3–9 and the development of complex human diseases such as cancer10–14.
Functional study of miRNA largely depends on the reliable identification of miRNA-mRNA regulatory interactions. Most state-of-the-art computational prediction methods, such as miRanda15, RNA2216, DIANA-microT17
and Targetscan18, are focused on primary search for nucleotide sequences complementary to the miRNA seed
region (2nd–8th bases on the 5′ end)18 and suffer from high false prediction because of the dramatic complexity in
miRNA binding19,20. Recent sequencing-based interactome data provide different views in this issue. For examples, through the crosslinking, ligation, and sequencing of hybrids (CLASH) analysis21, 18,514 miRNA-mRNA
interactions were detected and only ~22% were associated with seed region, via either contiguous or gapped
complementary RNA base pairing. The same study also unveiled that ~60% of the binding sites are within
coding region of mRNA, as opposed to the 3′UTR centric search by the existing algorithms. Similar findings
were observed using the covalent ligation of endogenous Argonaute–bound RNAs (CLEAR)-CLIP in human
hepatoma (Huh7.5) cells, where ~26% of the interactions are seed-associated and ~57% are non-3′UTR interactions22. In addition, compelling evidence also shows the stochastic nature of miRNA-mRNA interactions that 1)
multiple miRNAs can bind to the same mRNA sequence or different copies of the same transcript - combinatorial
interactions23–26 and 2) multiple different mRNAs, possibly along with other long non-coding RNAs and circular
RNAs27–29, can compete for binding to the same miRNA - competitive interactions23,30–32, which is very similar
to transcription factor (TF) regulation33,34. Other factors, including genetic mutations35–38, the competition with
other RNA binding proteins39,40 and the conditional expression of miRNA and mRNA41 can also affect the status
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Figure 1. Discovery of dynamic and modularized miRNA regulation during cancer progression. (A) The
identification pipeline of conditional miRNA regulatory interactions; (B) Meta-Lasso Regression approach to
the detection of microRNA regulators of each gene in each cancer stage.

of miRNA-mRNA interactions. Each of these mechanisms stresses the dynamic miRNA regulation from a different perspective and many of them are conditional (e.g., associated with certain phenotypes or development
stages). It is notable the conditional information can be captured by genomic data collected under associated
conditions. However, to the best of our knowledge, currently there is no systematic assessment available on the
dynamic miRNA regulation that assesses the changes across conditions. The first such attempt, reported in24, only
briefly touched the combinatorial module that a set of miRNA can regulate a common set of targets in a specific
condition, which hinders the practical use as a dynamic system.
We notice that the actual challenges in tackling dynamic miRNA regulation involve several major trends. First,
while the reliable stratification of gene regulation networks has been lagging, the associations between miRNAs
and TFs were reported in different scenarios26,42–44. For example, one TF gene, CTCF, controls the expression of
HOXC5, which is the host gene of miR-615-3p45,46 while miR-615-3p interacts with CTCF transcript in CALSH
experiment21. This type of bi-directed regulation between TF and miRNA may introduce the feedback loops to
the whole gene regulation network. Likewise, in order to determine the miRNA-mediated regulation on gene
expression, one should also consider other major gene regulatory factors, such as copy number variation (CNV)
and DNA methylation47. Secondly, evidence also shows that multiple miRNAs can regulate a set of functionally
relevant genes instead of the same gene in a cooperative manner, e.g., miR-17-5p, -18a-5p, -19a-3p, and -92a3p co-regulate 44 functionally related genes, such as CCND2, TNRC6B, and PHF1248. Although our knowledge of cooperative miRNA regulation is extremely limited, it is envisioned that the mechanisms underlying TF
non-complex co-regulation49,50 can be adopted in miRNA study.
In this study, we propose a new method to identify dynamic miRNA-gene interactions, particularly focusing
on the conditional interactions that are associated with tumor progression, based on the integration of heterogeneous genomic information on multiple human cancers. Other gene expression regulators such as TF, CNV, and
DNA methylation have also been considered when determining miRNA-mediated gene regulatory networks in
each developmental stage of cancer. Moreover, we demonstrated the discovery of modularized miRNA regulation
based on the identified miRNA-gene interactions.

Results

The workflow of this study is demonstrated in Fig. 1 with the detailed methodologies explained in Methods. We
applied the proposed pipeline on cancers from seven tissues including lung, kidney, stomach, breast, liver, uterine,
and pancreas, and have identified miRNA-mRNA interactions associated with each specific cancer. Note that the
interactions were identified in the regulator detection step (Fig. 1B), which was performed for each cancer and
each stage. While the complete results were archived in our online database (http://sbbi.unl.edu/miRDR), main
discoveries were presented in the following sections. Particularly, we focused on the kidney and lung cancers and
compare our discoveries between two well-defined subtypes, i.e., Kidney Renal Clear Cell Carcinoma (KIRC) versus Kidney Renal Papillary Cell Carcinoma (KIRP), and Lung Adenocarcinoma (LUAD) versus Lung Squamous
Cell Carcinoma (LUSC).

Transcript availability and binding affinity are not the only factors in miRNA regulation. After

reanalyzing CLASH data (details in Methods), 17,400 miRNA-mRNA interactions resulting from 17,651
high-confidence binidng sites have passed the quality-filtering step and remained for the downstream analysis.
Figure 2A shows the abundance distribution of these interactions and Fig. 2B shows the distribution of corresponding corrected p-values from the Binomial test. 95.3% of the interactions have their counts significantly
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Figure 2. Overview of the interactions detected by the CLASH analysis. (A) Distribution of the miRNA-gene
interactions (y-axis) with respect to their abundances (x-axis). (B) Distribution of the corrected p-values of each
interaction from Binomial test for quality filtering. (C) Projection of each interaction based on the abundance
of the corresponding miRNA (x-axis), mRNA (y-axis), and interaction (z-axis). (D) The relationship between
the abundances of each miR-92a-3p interaction and the corresponding mRNA. The colored points indicated
the three levels of binding affinities based on MFE values: High (red, [−31.2, −21.8]], Medium (green, [−21.8,
12.3]), and Low (blue, [−12.3, −2.9]).

higher compared to random interaction (p-value ≤ 0.05 after Bonferroni multiple test adjustment). Detailed statistics were provided in Supplementary Table S2.
We also observed weak correlations of miRNA regulatory interaction abundance with both mRNA and
miRNA abundance (Fig. 2C). For example, 57.9% of miRNAs has Pearson correlation coefficient r ≤ 0.03 between
the abundance of their target mRNAs and the number of interactions, contradicting the generally-believed
assumption that miRNA binds to its different mRNA targets proportionally with respect to their sequence availability. Figure 2D shows that the most “versatile” miRNA, i.e., miR-92a-3p, regulates 956 different mRNAs through
1,065 different interaction sites. The interaction counts range from 63 to 23,870 (Mean = 296.5), significantly
correlated with the corresponding mRNA abundance (r = 0.26). Similar weak correlations were also observed
between binding affinities, e.g., minimum free energy (MFE)51, and interaction abundances (r = 0.01).
In summary, these findings suggest that in addition to mRNA sequence availability and binding affinity, there
must be some other factors impacting the miRNA-mRNA binding, which makes miRNA regulation a highly
selective process. For example, one possible factor can be mRNA structure that determines the accessibility for
miRNA binding.

MiRNA-mRNA interactions can be specific to cancer type and stage. The initial analysis of
genomic data has identified differentially expressed (DE) genes and miRNAs in different stages of cancer (summary statistics are in Supplementary Table S3 while more details are available online). Many changes were found
to be stage-specific. For example, there are 4,273 DE-genes with fold-change (FC) over 2 (fold) in at least one stage
of KIRC, but only 21.2% (908) of them have more than 2-fold changes in all four stages. Similar observations were
made on miRNAs, i.e., 174 DE-miRNAs were identified in KIRC and only 43.7% (76) were consistent across all
stages. This analysis provides a list of 15,901 genes and 419 miRNAs that are cancer-associated for downstream
analysis. However, this simple correlation analysis each time only checks one pair of miRNA and mRNA. It fails to
acknowledge the fact that in reality there can be multiple miRNA regulators for one individual gene. Considering
the fact of simultaneous multiple interactions, we turn to our proposed pipeline to solve this issue.
Using our meta-Lasso regression approach (Methods), we predicted interactions between miRNA
and miRNA-targetable genes under each cancer developmental stage. Overall, there were 14,554 unique
miRNA-mRNA interactions identified across all conditions. Similar to DE genes and miRNAs, those interactions tend to be cancer stage- or type- specific. Figure 3A shows the statistics of interactions identified in each
cancer and each stage where the blue bars indicate the portion specific to the corresponding stage within that
cancer type. First, we observed in most cancers (8 out 9), miRNA interactions are more abundant in early stages
(Stage I + II) compared to the advanced stages, which highlights the miRNA’s implication in the early cancer
progression. In total, 73.7% of the interactions are detected in only one stage of that cancer. In different stages of a
cancer, the same miRNA may regulate different genes while the same gene can be regulated by different miRNAs.
SCIEntIfIC REPOrTS | 7: 13356 | DOI:10.1038/s41598-017-13470-5
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Figure 3. Overview of the miRNA-mRNA interactions identified in nine cancers. (A) Number of interactions
detected in a specific stage (Blue) versus multiple stages (Orange), in each cancer. (B) Pie chart shows the
percentages of interactions shared by different cancers.

Figure 4. Illustration of the dynamic miRNA-mediated gene regulation (miRNA: pink diamonds and genes:
purple nodes). (A) Three miRNAs regulate HOXA11 gene in different stages of KIRC. (B) Five miRNAs
repress the same KIF1C gene in KIRC while the miR-484 and miR-769-3p (pink diamonds with red border)
consistently interact with KIF1C across stages.

For example, a kidney developing gene, Homeobox A11 (HOXA11), was regulated by three miRNAs in KIRC
and suppressed expression was observed during progression (3-fold, miR-769-3p (Stage I); 2.9-fold, miR-484
(Stage II); 2.1-fold, miR-30d-5p (Stage III); 2.2-fold, none (Stage IV)) (Fig. 4A). Similar observation was made on
Kinesin Family Member 1 C (KIF1C) gene: five miRNAs interacted with KIF1C in three stages of KIRC (1.8-fold,
miR-484 and miR-769-3p (Stage I); 1.9-fold, miR-1260b, let-7b-5p, miR-149-5p, miR-769-3p and miR-484 (Stage
II); 2.0-fold, miR-769-3p (Stage III); 2.2-fold, none (Stage IV)) (Fig. 4B). This may indicate that different miRNAs
can play a similar role in cancer development by targeting the same target.
In addition to the low consistency across stages of the same cancer, we also observed limited common miRNA
regulatory interactions across cancers. Up to 92.7% (12,742) of the interactions were shared by less than five types of
cancer and 22.8% (3,142) were identified specifically in one cancer type (Fig. 3B). Interestingly, even within the same
tissue type, the number of common interactions across cancer subtypes was much lower than expected, e.g., 17.8%
(1,264 out of 7,118) between KIRC and KIRP and 16.2% (1,051 out of 6,496) between LUAD and LUSC. This may
be explained by the distinct expression profiles of genes and miRNAs in different subtypes of cancer. For example,
KIRC and KIRP only share 34.5% of 6,332 DE genes and 23.5% of 136 DE miRNAs. The distinct miRNA regulatory
patterns among stages and cancers demonstrate again the conditional feature of miRNA regulation. Moreover, it
signifies that some miRNAs can only contribute to certain types or phases of tumor developments.

Functional implication of miRNA regulation in kidney cancers. To assess the functional impacts
of miRNA regulation in cancer progression, we further examined the interactions identified in two subtypes of
kidney cancer (KIRC and KIRP), particularly focusing on those associated with cancer driver genes reported by
Vogelstein et al.52. Per our identification, 19 cancer genes were regulated by miRNAs in both early-stage KIRC
and KIRP (purple nodes in the upper panel, Figure S1), where only 16 out of the 118 related interactions are commonly shared by both cancers (red edges) and 12 genes are regulated by totally different miRNAs. For example,
Neurogenic Locus Notch Homolog Protein 2 gene (NOTCH2) was regulated by miR-744-5p, -25-3p, -92a-3p,
and -27b-3p in KIRC and by miR-744-5p, -106a-5p, -130b-5p, and let-7c-5p in KIRP. Another critical cancer
SCIEntIfIC REPOrTS | 7: 13356 | DOI:10.1038/s41598-017-13470-5
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suppressor gene TP53 was regulated by miR-454-3p in KIRC, and by miR-324-5p and -222-3p in KIRP. On the
other hand, we observed that common miRNAs regulated different targets in two cancer subtypes. Among 27
common miRNAs, 65.0% of the interactions were linked to different cancer genes in both early-stage tumors.
Given the distinct mechanisms underlying the development of these two subtypes of cancer53,54, we are also
interested in exploring how miRNA regulation contributes to the general or divergent growth of kidney cancers. Pathway and gene ontology (GO) enrichment analysis was performed using The Database for Annotation,
Visualization and Integrated Discovery (DAVID v6.8)55 based on the suppressed genes in the early-stage cancers.
Table 1 lists the top enriched KEGG pathways that are either common or specific in KIRC and KIRP (selected
according to p-values and the complete list of GO and pathways are provided in Supplementary Table S4). Among
the three common pathways (PI3K-ATK signaling pathway, Cell cycle, and Thyroid hormone signaling pathway),
22 genes were miRNA-regulated in the early-stage kidney cancer and 9 of them occurred in both subtypes. Only
7 miRNA-gene interactions were observed in both subtypes, which indicates that the same functional regulation
can be realized by miRNAs interacting with different gene targets.
Figure 5 demonstrates how miRNAs regulated PI3K-Akt signaling pathway (in 5 A) and cell cycle pathway
(in 5B) in early-stage KIRC and KIRP through various conditional interactions. For example, the common genes
(purple nodes), e.g., TSC1, MYC, and CDKN2A, were targeted by different miRNAs in two cancer subtypes while
the common miRNA regulators (pink diamonds with red border), e.g., miR-320a, -17-5p, and 92a-3p, can interact with different targets, which leads to a different set of interactions that control the same functional pathway.
Moreover, within the cancer-specific pathways, the distinct miRNA regulation patterns (Table 1) also provide new
insights into cancer subtyping in the miRNA regulation perspective. In addition, similar observations were found
by comparing LUAD and LUSC (Supplementary Table S5).

Prediction of miRNA regulatory modules.

Based on consistent observations in all nine cancers, we
hypothesized that miRNAs can exert a regulatory role in certain biological functions through interacting gene
targets that may be different across conditions. Moreover, multiple miRNAs can effectively cooperate in the same
functional pathway by repressing the same or associated targets. Therefore we conducted a module detection
based on the miRNA-gene interactions derived from the previous steps (Methods). As a result, 4,134 miRNA
modules were identified and each included a set of 4–5 miRNAs consistently co-regulating the same set of pathways across more than two cancer conditions. Table 2 lists the summary statistics on the derived modules and
details are provided in Supplementary Table S6.
We observed that most miRNA modules play their regulatory roles in different stages of cancer, and that only
a small proportion is common across cancers. As expected, we observed in each single module that miRNAs
coregulate one or multiple module, miRNAs co-regulate one or more biological processes through co-binding
to the same target or different targets in the same pathway across conditions. Table 3 provides an example of a
4-miRNA module that regulates two pathways (glycolysis and focal adhesion) in three cancers (KIRC, LIHC, and
UCEC). Under different conditions, miRNAs tend to target different genes but miR-320a always interacts with
the same gene (PKM2) when regulating the glycolysis pathway. Figure 6 illustrates how the same miRNA module
regulates critical signaling transduction genes in the focal adhesion pathway. For example, MET and LAMB1/
COL4A1/LAMA5 were regulated in different stages. Since those genes are the initial activators and triggers in
focal adhesion, the regulatory model is capable of controlling the whole process more efficiently by each miRNA
member targeting different genes under different stages.

Validation of identified regulatory interaction in cancers. Through comparison, 2,014 miRNA-gene

interactions of our prediction have been annotated as experimentally validated entries in miRTarBase56, which
are reported by various assays, such as Luciferase reporter assay, qRT-PCR or Western blot analysis with miRNA
transfections (Supplementary Table S7).
To further validate the interations in cancer, we also performed an extensive literature search on all miRNA/
cancer-related publications during 2001–2017 in PubMed database by utilizing the NCBI API tool. First, we
searched for articles that mentioned the predicted miRNA- mRNA pairs in the corresponding cancer type, e.g.,
let-7a-5p-HMGA1 in breast cancer. Then we examined all 27,586 returned articles to confirm if the experimental
evidence for a direct interaction is strong or not based on the experimental assays that have been used. Note that
the negative expression correlation is not considered as strong evidence of direct interaction in our analysis. As a
result, 43 miRNA-mRNA interactions associated with the nine types of cancer have been validated (Table 4). It is
not surprising that those interactions are related to a few well-known cancer-associated miRNAs such as let-7a,
miR-181a, and 200c, which reflects the reality that most of current experimental efforts are still on the assessment
of well-reported targets in various cancer conditions. We believe computational prediction like ours can bring
more new targets in this direction.

Model Quality Assessment.

Robustness of the proposed method was assessed based on the consistency
of regulator detection across datasets with various sample sizes. Take the 251 samples from stage I of KIRC as an
example. For each size i (5<=i<= 251), we randomly generated or each integer i from 5 to 251 (maximum sample size), we randomly generated 1000 testing data sets with the sample size. We conducted regulator selection for
each gene based on the final model in the meta-Lasso regression analysis on each dataset. The consistency across
models with different sample sizes was evaluated by comparing the similarity of the selected regulators. Figure 7A
shows the comparisons on these selected regulators based on three genes (CARD11, JAK2, and HMGA1), and
a high-level stability of our model with the increasing sample size was observed. Moreover, for miRNA regulator identification (Fig. 7B), we found that our method has reached the high-level consistency for CARD11 and
HMGA1 (JAK2 were not regulated by miRNAs in this stage).
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Common

KIRC-Specific

KIRP-Specific

Enriched Pathways

Interactions in KIRC

Interactions in KIRP

PI3K-ATK Signaling Pathway

MYC-miR-17-5p; TSC1-miR-320a;
PPP2R1A-miR-106a-5p/ -941;
TP53-miR-454-3p; JAK1-miR-15b5p; JAK2-miR-195-5p; PTEN-miR181b-5p

MYC-miR-17-5p/ -320a/ -423-5p/ -744-5p/ let7b-5p; TSC1-miR-320a; PPP2R1A-miR-17-5p/
-222-3p/ -92a-3p; TP53-miR-222-3p/ -324-5p;
CCND1-miR-15a-5p/ -193b-3p/ -196a-5p/ -92a3p; FGFR2-miR-186-5p; MAP2K1-miR-93-3p;
NRAS-miR−877-3p; STK11-miR-17-5p

Cell Cycle

CREBBP-let-7e-5p/miR-1301-5p;
MYC-miR-17-5p; TP53-miR-4543p; EP300-miR-30c-5p; ATMmiR-3144-3p/ -92a-3p; CDKN2AmiR-455-3p; STAG2-miR-193b-3p;
ABL1-let-7b-5p

CREBBP-let-7e-5p/ miR-1301-5p/ -935;
EP300-let-7b-5p/ -193b-3p/ -92a-3p; MYCmiR-17-5p/ -320a/ -423-5p/ -744-5p/let-7b-5p;
TP53-miR-222-3p/ -324-5p; CDKN2A-miR320a; CCND1-miR-15a-5p/ -193b-3p/ -196a-5p/
-92a-3p

Thyroid Hormone Signaling
Pathway

CREBBP-let-7e-5p/miR-1301-5p;
MYC-miR-17-5p; NCOA3-miR20a-5p; NOTCH2-miR-744-5p/
-27b-3p/ -25-3p/ -92a-3p; TP53miR-454-3p; EP300-miR-30c-5p;
CTNNB1-miR-744-5p

CREBBP-let-7e-5p/miR-1301-5p/ -935; MYCmiR-17-5p/ -320a/ -423-5p/ -744-5p/ let-7b-5p;
NCOA3-miR-20a-5p; NOTCH2-miR-744-5p/
-106a-5p/ -130b-5p/ let-7c-5p; TP53-miR-2223p/ -324-5p; EP300-let-7b-5p/ -193b-3p/ -92a3p; CCND1-miR-15a-5p/ -193b-3p/ -196a-5p/
-92a-3p; NRAS-miR-877-3p; MAP2K1-miR-933p; MED12-miR-454-3p

Herpes Simplex Infection

CREBBP-let-7e-5p/miR-1301-5p;
TP53-miR-454-3p; EP300-miR-30c5p; JAK1-miR-15b-5p; JAK2-miR195-5p; PTEN-miR−181b-5p;
PTPN11-miR-130b-3p/ −183-5p/
−193b-3p

Transcriptional Misregulation

MYC-miR-17-5p; TP53-miR-4543p; ATM-miR-3144-3p/ −92a-3p;
CEBPA-miR-744-5p; H3F3A-miR100-5p; MEN1-miR-17-5p

Jak-STAT Signaling Pathway

CREBBP-let-7e-5p/ miR-1301-5p;
MYC-miR-17-5p; EP300-miR-30c5p; JAK1-miR-15b-5p; JAK2miR-195-5p; PTEN-miR-181b-5p;
PTPN11-miR-130b-5p/ -183-5p/
-193b-3p

MAPK Signaling Pathway

MYC-miR-17-5p/ -320a/ -423-5p/ -744-5p /
let-7b-5p; TP53-miR-222-3p/ -324-5p; BRAFmiR-191-5p / -744-5p; FGFR2-miR-186-5p;
MAP3K1-let-7g-5p/ miR-423-3p; MAP2K1miR-93-3p; NRAS-miR-877-3p

Rap1 Signaling Pathway

GNAS-miR-331-3p; BRAF-miR-191-5p/ -7445p; FGFR2-miR-186-5p; MAP2K1-miR-93-3p;
NRAS-miR-877-3p

Central Carbon Metabolism

MYC-miR-17-5p/ -320a/ -423-5p/ -744-5p/
let-7b-5p; TP53-miR-222-3p/ -324-5p; FGFR2miR-186-5p; MAP2K1-miR-93-3p; NRAS-miR877-3p

Table 1. Illustration of the common and cancer-specific pathways and the miRNA-mRNA interactions
involved in KIRC and KIRP. *Underline indicates the common interactions between KIRC and KIRP and Bold
denotes the same genes or miRNAs involved in KIRC and KIRP.

To further demonstrate the performance of miRDR, we also conducted a peer comparison with two other
well-established methods: RACER57 and MCMG58, on miRNA target prediction using expression data. The test
dataset was collected from 332 patients in LIHC, available at the TCGA website59, along with 34,986 experimental
miRNA-target interactions detected by CLEAR-CLIP in Hepatocellular carcinoma cell (Huh-7.5)22. We utilized
three methods to predict the miRNA-target interactions in each stage of LIHC. First, we found that RACER and
MCMG predicted significant more interactions than miRDR (average number of predicted interactions: miRDR
1,634; RACER 10,371; MCMG 212,171) but less experimental validated interactions among the top ranked ones.
When taking a close look at each stage, we ranked the predicted interactions from RACER and MCMG according
to the score and compare with top-n predictions from miRDR at 100-intervals (Fig. 8A). It is clear that miRDR
outperformed two other methods by identifying significantly more validated interactions in each stage (p-value
of one-sided Wilcoxon singed rank test is shown in the figure). Moreover, unlike RACER and MCMG, miRDR’s
performance was not affected by the input sample size. For example, RACER and MCMG predicted only half
validated targets in smaller sets (in stage II (82), III (80) and IV (6)) than what they did in a bigger set (stage I
(164)) among top-1000 predictions. At another evaluation, we compared the distribution of miRNA target count
predicted by three methods, using the experimental data from CLEAR-CLIP as reference. As Fig. 8B shows, the
distribution of miRDR is very close to the experimental one, while RACER and MCMG tend to predict too many
more targets for most miRNAs.
Although Lasso regression method is capable of handling the problem of more variable than samples60, we still
recommend a minimum number of samples for each gene for using our meta-Lasso regression model in order
to reach high confidence in the inferred miRNA regulators. Note these thresholding values also depend on the
numbers of possible regulators each gene can have (Supplementary Table S8).
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Figure 5. MiRNA-mediated gene regulation involved in two functional pathways in the early stage of KIRC
and KIRP (miRNAs: pink diamonds; genes: ellipses). (A) PI3K-Akt Signaling Pathway; (B) Cell Cycle Pathway.
Purple nodes denote the common genes between KIRC and KIRP; pink diamonds with red border indicate the
common miRNA regulators; green ellipses are the condition-specific cancer genes.

# of consistent modules across >= 2 conditions
Cancer-Specific

General

Module
sizes (k)

# of k-miRNA # of modules reflecting
Modules
significant pathways
Total

In 2 stages
of a cancer

In > 2 stages
of a cancer

In 2
cancers

In > 2
cancers

1

285

4

—

—

—

—

—

2

6,276

641

—

—

—

—

—

3

149,449

15,383

—

—

—

—

—

4

229,801

23,044

2,349

2,127

—

219

3

5

1,711,669

83,711

1,785

1,728

—

57

—

Table 2. Statistics of the miRNA regulatory modules.

Software and database access. We have developed a microRNA Dynamic Regulation Database (miRDR)
that archives all the identified miRNA regulatory modules in each cancer online at http://sbbi.unl.edu/miRDR.
An R package implementing the proposed method is available for download from our miRDR webpage.

Discussion

In this study, we presented two important characteristics of miRNA regulation. Dynamic regulation refers to
the fact that the same miRNAs interact with different targets under different conditions. Theoretically speaking,
factors contributing to the dynamic property of miRNA regulation may include the distinct expression of miRNA
and their target, potential SNPs involved in the binding site, DNA translocation in the gene region, competitive
binding between miRNA and other RNA binding proteins. On the other hand, modularized regulation describes
that miRNAs may cooperate when they target to the same gene or same functional process across different conditions. Intuitively speaking, when multiple miRNAs target the same process, especially when multiple genes
are controlled (Fig. 6, Table 5 and Supplementary Table S6), they render higher efficacy in terms of functional
regulation.
Through heterogeneous genomic data integration, modeling, and adjustments of gene expression based on
other regulatory mechanisms such as TF and CNV, we have detected 14,554 conditional miRNA-gene interactions in 9 types of cancer. The discrepancy between the inferred interactions from our pipeline and the
CLASH-reported interactions may be explained by the fact that the former reported conditional interactions
highly associated with cancers while the latter reported interactions associated with AGO1 protein in HEK293
cell. To generalize the CLASH reported miRNA-gene interactions to different cell types, we also designed a filtering process to minimize the possibility of overuse. Gene expression and miRNA expression have been assessed to
ensure both molecules have a meaningful expression in the cell of interest. We also checked if any somatic mutation occurs at the CLASH reported binding site on mRNA sequence in the new cell line. The design of miRNA
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Conditions (Cancer/Stage)
Pathways

Glycolysis /
Gluconeogenesis
Pathway

Pathways

Focal Adhesion

KIRC

LIHC

UCEC

MicroRNAs

Stage 1

Stage 2

Stage 1

miR-18a-3p

PGK1, PKM2

PKM2

PKM2

miR-320a

PKM2

PKM2

PKM2

miR-193b-3p

GPI, PGAM1

GPI, ALDH3A2,
ALDH7A1

GPI,
ALDH3A2,
TPI1

miR-92b-3p

PGAM1

ALDOA

PGAM1

KIRC

LUSC

UCEC

Stage 1

Stage 1

Stage 1

miR-18a-3p

PAK4, PIK3R3

COL4A1

COL4A1

miR-320a

ACTB, CCND2

PAK1, CCND2

LAMA5, MET

miR-193b-3p

LAMB1

FLNA, RAPGEF1,
VAV2

CCND1,
PTEN, PAK2,
PIP5K1C,
COL4A1

miR-92b-3p

ACTN4, PARVG,
PPP1CB

FLNB, MAPK1

ACTN4, FLNA,
MAPK1,
PARVG, TLN1

MicroRNAs

Table 3. An illustration on a 4-miRNA module (miR-18a-3p, -320a, -193b-3p and -92b-3p) that regulates two
signaling pathways in three conditions. Gene targets are listed for each pathway and each condition.
regulatory score enables an efficient differentiation among miRNA-mRNA interactions. In contrast to the existing methods that evaluate the interactions based on simple features such as binding affinity or complementary
sequences, our miRNA scoring system learned and considered more features directly from experimental data,
which is expected to be more reliable.
Comparing with two leading algorithms for miRNA target prediction based on expression profiles, miRDR
has showed its advantageous predictive power with two major improvements. First, comparing with other methods, miRDR’s predictions tend to include more validated interactions while not introducing significant high false
prediction. This is an important aspect given the widely-accepted critique on high false positive rate in current
target prediction. Another advantage was the stable performance of miRDR on fairly limited sample size. The
meta-analysis design minimized the impacts of sample variation on the target prediction, which seems promising
to facilitate the detection of weak signals between miRNA and targets with insufficient samples.
Overall, our knowledge of modularized miRNA regulation is still very limited. Along this line, Ding et al.
identified 181 modules based on a simple statistical analysis on CLASH reported interactions24. In this study, we
have identified 4,134 functional miRNA modules based on the consistent miRNA co-regulation across different cancer conditions, where all previously reported modules are covered. Note the previous study focused on
miRNAs that target the same gene while our method assesses comprehensively all modules involved in similar
functional processes, which therefore can be more general. For example, one novel 5-miRNAs module, namely
miR-196a-5p, -196b-5p, -365a-3p, -378a-5p and -30b-5p, has been identified to regulate cell cycle and MAPK/
Wnt singling pathways in kidney and uterine cancers in our study. It was also conceived as a functional module
by Trajkovski et al. where they uncovered that these miRNAs cooperatively promote the brown adipogenesis
pathway in mice61.
In addition, since new sequencing technologies such as CLASH and CLIP can produce non-overlapped data
on miRNA interactome, future inclusion of interactions detected in different platforms and cell types is expected.
The concern of minimum sample size for reliable detection of regulators for each gene using our meta-lasso
regression approach is actually a common concern of all similar analysis. We envision controlling the initial set of
regulators including both TFs and miRNAs may alleviate this concern.

Conclusion

In summary, we proposed an integrative computational method to identify reliable miRNA-gene interactions
in a given biological condition based on the integration of heterogeneous genomic data. In order to stratifying
complex gene regulation networks, our approach considers other gene-expression regulatory factors including
TF regulation, CNV, and DNA methylation. Applying the meta-lasso regression approach to 9 types of cancer,
we have examined in-depth all possible miRNA-mRNA interactions and regulatory modules that are involved
in different phase of cancer progression. The observed properties of the identified interactions further demonstrated the dynamic feature of miRNA regulation during tumor progression. We hope the method developed in
this study can provide the community a promising solution to overcoming scientific limitations in the study of
dynamic miRNA regulation in complex systems by generating novel insights in dynamic targeting and dramatically reducing the extensive lab-load in related research areas.

Methods

Data preparation. Data used in this study are all publically available, including (1) raw sequencing reads of
miRNA-mRNA interactions from the CLASH experiment21 (GSE50452); (2) DNA binding data of 150 TFs from
large-scale ChIP-Seq analysis by the Encyclopedia of DNA Elements (ENCODE) Consortium45; (3) multi-level
SCIEntIfIC REPOrTS | 7: 13356 | DOI:10.1038/s41598-017-13470-5
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Figure 6. Illustration of the cooperative regulation of a miRNA module that contains four miRNAs: miR18a-3p, -320a, -193b-3p, and -92b-3p (pink diamonds). This miRNA module consistently regulates the Focal
Adhesion pathway in KIRC, LUSC, and UCEC. The target genes are color-coded (each color represents one
cancer condition and the bi-colored nodes indicate the corresponding genes have been regulated by miRNAs
in two conditions). The detailed miRNA-gene interactions are listed in Table 3. The network is visualized using
Cytoscape 3.2.0 72 with KEGGscape73 plugin.

genomic data from 4,206 patients and 9 types of cancer from Cancer Genome Atlas (TCGA)62 including miRNA
and mRNA expressions, CNVs, and DNA methylation data (Table 5). In addition, for each cancer patient, stage
and subtype information was also retrieved from TCGA.

CLASH data reanalysis. To assess the detection confidence level of CLASH reported binding sites, we
first reanalyzed the raw sequencing data from CLASH and performed reads mapping against human reference
genome (HG19) and human mature miRNA sequences database (miRBase63, version 21). Then, three types of
reads were examined for each miRNA-mRNA binding site in the CLASH experiment including (1) chimeric
reads that represent miRNA-mRNA binding sites; (2) miRNA single reads that represent free miRNAs, which
are unbound with any mRNAs; (3) mRNA single reads that represent unbound mRNA sequences, which are
unbound with any miRNAs.
Binomial test was applied on each binding site to infer the detection confidence level of a specific binding site
k between miRNA i and the mRNA j. Specifically, the chimeric reads count of interactions between miRNA i and
mRNA j at the binding site k, Cijk was assumed to follow a binomial distribution Cijk ∼ Binomial Call , Pijk under
the null hypothesis, where Pijk (equation (2)) represents the probability of a binding occurred between miRNA i
and mRNA j at the binding site k. Binomial test was performed and the p-value for each miRNA-mRNA binding
site was calculated by the formula

(

p − valueijk =

Call

Call

Cijk

ijk

∑(C

C
)Pijk
(1 − Pijk)Call−C

)

(1)

where Call is the count of chimeric reads supporting all interactions and the probability of a binding occurred
between miRNA i and mRNA j at the binding site k is estimated by
Pijk =

Cijk
Sumi

×

Cijk
Sumj

(2)

where Sumi and Sumj represent the total reads counts (chimeric reads and single reads) associated with miRNA
i and mRNA j, respectively. Binding sites with Bonferroni-multiple-test-adjusted p values less than 0.05 were
considered to be significant and included in the further analysis.

Regulatory score (RS) calculation of each miRNA-mRNA pair. To assess the likelihood of interactions between a potential target mRNA and a miRNA, we designed a probability-based regulatory score. As
introduced above, we first estimated the probability of an interaction event between miRNA i and mRNA j at the
binding site k by the equation (2), which we denoted as Pijk.
SCIEntIfIC REPOrTS | 7: 13356 | DOI:10.1038/s41598-017-13470-5
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microRNAs
hsa-let-7a-5p
hsa-miR-10a-5p

Genes
DICER1
HMGA1
EPHA4
HBP1

hsa-miR-17-5p
hsa-miR-181a-5p

MYC

hsa-miR-196a-5p

1, 4

BRCA74,75

2, 4
2, 4

LIHC76
BRCA77,78

1, 2, 4

STAD79

DDX3X

UCEC80

2, 4

PAAD81

1, 2, 4

YWHAZ
CCND1

STAD82

3, 4

FOXO1

LUAD83

1, 4

HOXA7

LUAD84

HOXB8
HOXC8

hsa-miR-196b-5p

Techniques

UBE2C
CCND1
hsa-miR-193b-3p

Cancers

HOXC8

LUAD/LUSC84
BRCA85

3, 4

1, 3, 4

LUSC85
BRCA86
KIRC/KIRP87
LIHC88

hsa-miR-200c-3p

ZEB1

LUAD/LUSC89

1, 2, 3, 4

PAAD90
STAD91
UCEC92
hsa-miR-210-5p
hsa-miR-221-3p

ISCU
ATXN1
BCL2L11

LIHC93
LUAD/LUSC94

1, 3, 4

BRCA95–97

1, 3, 4

hsa-miR-222-3p

PPP2R2A

LUSC98,99

3, 4

hsa-miR-23b-3p

PSAP

LUSC100

1, 2, 3, 4

hsa-miR-26a-5p

HSPA8

BRCA101

2, 4

MTDH

LUAD/LUSC102

RAB18

LUAD103

HOXA11

UCEC104

MYC

LIHC105

VDAC1

UCEC106

hsa-miR-424-5p

WEE1

KIRC107

1, 2, 4

hsa-miR-744-5p

TGFB1

KIRC/ KIRP108

2, 4

hsa-miR-30c-5p
hsa-miR-30d-5p
hsa-miR-320a

2, 4
1, 2, 4

Table 4. Detailed information of validated interactions from literatures. Validation Techniques: (1) Luciferase
reporter assay, (2) quantitative RT-PCR, (3) Western blot analysis, (4) miRNA transfection.

Then, raw RS of each miRNA-mRNA pair was calculated by the aggregation of the binding probability and the
binding affinity, e.g., represented by the MFE51 of the corresponding interactions, as follows:
RSij =

1 K
∑ MFEk × Pijk
K k= 1

(

)

(3)

where MFEk represents the minimum free energy of the binding site k and K is the total number of different binding sites between miRNA i and mRNA j.
To mimic the situation of competition among mRNAs on the same miRNA, raw RS was normalized by the
total number of potential targets associated with miRNA i:
RSij ′ = RSij /RSi .

(4)

where RSi. denotes the set of raw RS between all target j and miRNA i.

Regulatory score (RS) calculation of each TF-gene pair. Similar to miRNAs, a TF may also have more
than one binding site on a target gene. The RS for the TF t and gene j based on the binding site k was estimated
based on the distance (dtjk) between the binding site k and the transcription start site (TSS)47,64, as follows:
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Figure 7. Consistency assessments of regulator selection regarding difference sample sizes of three genes:
CARD11 (red, 28 potential regulators), JAK2 (blue, 73), and HMGA1 (green, 109). The lines denote the
transition Jaccard’s similarity of the regulators selected at different sample sizes of these genes. (A) Consistency
of all regulator selection across difference sample sizes. (B) Consistency of microRNA regulator selection across
difference sample sizes.

 1
4d tjk 
RStjk = exp− +

105 
  2

(5)

Because a smaller distance (dtjk) is associated with a higher regulatory potential of TF, RS for all binding sites
of a TF and gene pair can be aggregated as follows47:
RStj = 1 −

K

∏ (1 − RStjk)

k= 1

(6)

To mimic the situation that the same TF can bind to more than one gene, raw RS was normalized by the formula RStj ′ = RStj /RSt . where RSt . is the sum of RStj for a fixed t over all j’s.

Identification of the Conditional Gene Regulators through the Lasso Regression.

In this study,
we considered each stage of the nine types of cancer as an individual condition Dsc (stage: s = 1,2,3,4; cancers:
c = 1,2,…,9). For each gene under a specific condition, four matrices were constructed for a lasso regression
approach to identify the conditional TF and miRNA regulators (Fig. 9) including the following:
•

The expression vector Y of size (n × 1) represents the expression changes of gene j in each of the n cancer
patients associated with this condition versus healthy control. Here, in sample n, the expression changes of
gene j and miRNA i were calculated by comparing with the average expression in the normal control group
as follows:

(

∆gjn = log 2 gjn / gj

control

∆min = log 2(min / mi

•
•
•

)

control

)

(7)
(8)

where gj control and mi control denote the average expression levels of gj and mi among the normal control
samples.
The background matrix X1 of size n × 2 includes values of the copy number change and methylation of the
gene j in each cancer compared to the healthy control;
The regulator matrix P = [P1,…, Pn]T of size n × (r1 + r2) lists the expression changes of all regulators, including r1 TFs and r2 miRNAs, that interact with gene j, in each patient compared to the normal control;
The regulatory score matrix R of size 1 × (r1 + r2) lists the RS of each corresponding regulator to the gene j
derived from equations (4) and (6).

Based on the four matrices, a linear system is created as equation (9), where X2 = [P1 × R, …, Pn × R]T (inner
products of R and each row in P) represents the regulatory effects by TFs and miRNAs. The regulatory scores
in X2 denote the impacts of corresponding regulator (column) to the gene in a specific sample (row). Before we
solve the linear system in equation (9), the Frisch–Waugh–Lovell (FWL) method47,65,66 was applied to adjust
for the gene expression change caused by the background factors (CNV and methylation) through a linear
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Figure 8. (A) Method comparison on the identified miRNA-target interactions on the test set. MiRDR,
RACER and MCMG were applied on the Hepatocellular carcinoma (LIHC) data. The x-axis represents the top
ranked interaction predicted by miRDR while the y-axis represents the count of validated interactions. The
p-values were calculated by one-sided Wilcoxon singed rank test; (B) Method comparison based on the counts
of identified miRNA targets. X-axis: number of target genes; y-axis: miRNA percentage. Outer plot shows the
overall distribution and the inner shows the zoom-in view of partial distribution in the range of [0, 200].

Cancer Types

Normal

Stage I

Stage II

Stage III

Breast invasive carcinoma

BRCA

104

181

601

242

Stage IV
20

Kidney renal clear cell carcinoma

KIRC

71a

251

55

125

80

Kidney renal papillary cell
carcinoma

KIRP

71a

169

22

49

14

Liver hepatocellular carcinoma

LIHC

50

164

82

80

6

Lung adenocarcinoma

LUAD

58b

276

122

84

25

Lung squamous cell carcinoma

LUSC

58b

227

151

80

6

Pancreatic adenocarcinoma

PAAD

4

21

147

4

4

Stomach adenocarcinoma

STAD

32

55

119

174

42

Uterine Corpus Endometrial
Carcinoma

UCEC

33

331

48

121

28

Table 5. Detailed statistics of samples from nine cancer types. aThe same set of normal samples were used in
two type of Kidney cancers; bThe same set of normal samples were used in two type of Lung cancers.

transformation, and convert the linear system into equation (10). Then, Lasso regression60,67 was used to identify
the TFs and miRNAs that regulated the gene under the given condition.
Y = β1X1 + β 2X 2 + ε

(9)

MX1Y = MX1β 2X 2 + ε′ , where MX1 = I − X1(X1T X1)−1X1T

(10)

Meta-Lasso regression for robust regulator identification.

To minimize the bias caused by limited
cancer samples from TCGA and enhance the robustness in regulator selection, meta-Lasso regression68 was
adopted on regulator identification of each gene under each condition. The workflow is shown in Fig. 1B where a
hierarchical sampling and model integration was performed. Li et al. demonstrated that the meta-Lasso method
has the good consistency of selection and low false predication rate on several high-dimensional gene expression
data68. Here, we adopted the objective function of their meta-Lasso regressions to detect the most likely regulators
of each gene with the consideration of consistency across of multiple “individual” dataset:
P
P M


 M

max 
 ∑ l m βm 0, g , ζ m − w ∑ |gp| − λ ∑ ∑ |ζ mp|


β1 , g , ζ m = 1
p =1
p = 1m = 1





(

SCIEntIfIC REPOrTS | 7: 13356 | DOI:10.1038/s41598-017-13470-5

)

(11)

12

www.nature.com/scientificreports/

Figure 9. Four matrices constructed for each gene j and each condition, i.e., a specific cancer stage. Y represents
the vector of expression changes of gene j in the corresponding cancer patients under this condition; X1
represents the matrix of background adjustment factors (CNV and DNA methylation); R represents a RS vector
that contains the regulatory scores of all r1 TF- and r2 miRNA- regulators of gene j; P is the matrix that includes
all the expression changes of each regulator in each patient under the corresponding condition.

(

)

where l m βm , g , ζ m is the log-likelihood function of the m-th dataset; M denotes the number of individual data0
sets; gp is the effect of the p-th regulator (out of P regulators) at the overall condition; and ζmp is the effect of the
p-th regulator at the m-th dataset (out of M datasets).
Specifically, among the samples under one cancer condition, two rounds of 5-fold data separation were performed to generate 25 individual subsets that each contains a randomly selected 64% (80% × 80%) of the entire
samples (Fig. 1B). The final LASSO regression model was achieved by applying the meta-LASSO method to the
hierarchical sampled subsets. Any none-zero regression coefficients in the final LASSO model indicate the interactions occurred between the corresponding regulators and genes.
Subsequently, the same analysis was conducted for every human gene j in 36 conditions across all cancers
(4 × 9). As shown in the workflow (Fig. 1), we followed a hierarchical framework to identify cancer-specific regulations (based on the consistency across different stages of that cancer) and common cancer regulation (based on
the consistency across all cancers) through similar model selection procedure as described above.

Assessment of the model stability through a robustness test. To assess the robustness of this model,
particularly its dependence on the sample size, we performed regulator identification with different sample sizes
from p (the total number of potential regulators) to the total number of patients under that condition. We randomly generated 1,000 sets of data to perform the analysis at each sample size n, then evaluate the consistency
of the derived models by calculating the Jaccard’s similarity coefficient between selected regulators (L) between
model Fn (regulator selection using n samples) and its neighbor Fn-1 (using n-1 samples), as follows:
J (Fn, Fn −1) =

L(Fn) ∩ L(Fn −1)
L(Fn) ∪ L(Fn −1)

(12)

Assessment of potential miRNA-gene interactions in a specific cancer.

Although the reported
miRNA-gene interactions, e.g., 37,751 from miRTarBase56 database were validated in a particular experiment on
a certain type of cell, the same physical binding between the participating miRNA and gene can still be valid in
other cells as long as their sequences and expressions are conserved. With appropriate processing, we believe the
interactions obtained from one experiment can be conditionally generalized to other cell types. Specifically, for
each interaction, we conducted the following checkup when applying it to a new cell type:
•
•

both miRNA and gene must have meaningful expressions in the cell type of interest to maintain the activity
level of the interaction;
the annotated binding sites shouldn’t show any mutations in the new cancer cell. Otherwise, we would no
longer consider this binding site in the regulatory score calculation step.

In this proof-of-concept study, we focused on the experimental-validated binding sites from CLASH due to
the availability of raw sequencing read information that is required in our model for regulatory score calculation.

Detections of miRNA regulatory module based on functional involvement in cancers. Based
on the conditional miRNA-gene interactions derived from all cancers and stages, we explored the modularized
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miRNA regulation by examining their involvement in known functional pathways, i.e., 171 fundamental pathways from the KEGG database69. We exhaustively searched for all k-miRNA (k = 1–5) candidate modules where
miRNAs consistently regulated the same set of pathways across multiple conditions and evaluated the significance
in the following steps:
i. Under each condition, the miRNAs were linked to a set of KEGG pathways through their target genes.
Then, the miRNAs were grouped by the commonality on the same pathway as candidate modules
(k = 1–5);
ii. For each candidate module under one condition, a pathway enrichment analysis was conducted to ensure
the involvement of each pathway is statistically significant through a test based on the hypergeometric
distribution70:

Pr(rw|ND, pw , n) =

 p ND (1 − p )ND 

w
 w 
 rw  n − rw 

( Nn )
D

(13)

where ND denotes the total number of miRNA-regulated genes in the condition D, Pw represents the percentage of human genes associated with pathway w, n indicates the total number of target genes associated
with the module and rw is the number of genes belong to pathway w.
iii. A Binomial test was applied to assess the statistical significance of the involvement of |w|-pathways in a
miRNA module M
wMD ∼ Binomial(|W| , PWD)
∑171
w = 1(Total number of Modules with size k)wD
|W|( K )
k

PWD =

(14)

(15)

where k denotes the number of miRNAs in the module while K is the total number of miRNAs in this
analysis, i.e., 371; PWD denotes the overall probability of a k-miRNA group co-involves a common pathway
under condition D; wMD represents the number of enriched pathways associated with the k-miRNA module
M under condition D; | W | is the total number of functional pathways.
iv. Another Binomial test was utilized to examine the statistical significance of the recurrence of the candidate
module M across conditions.
dM ∼ Binomial(|D| , Pk)
Pk =

∑ 36
D = 1(Total number of Modules with size k)D
| D| ( K )
k

(16)

(17)

where k and K are defined in (14); Pk denotes the overall probability of a k-miRNA module associated with
common pathways across conditions; dM represents the number of conditions where the k-miRNA module
M is associated with common pathways; |D| is the total number of conditions.
Finally, we calculated False Discovery Rate (FDR) q-values from p-values using Benjamini’s method71. Module
candidates with q-values < 0.05 were reported as miRNA regulatory modules, i.e. we controlled FDR at 0.05 in
our integrative report of all miRNA module candidates with different k’s.
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